Is it safe?
Can MLYS take a bad year?
Mineralys Therapeutics, Inc. holds $138M more cash than debt, so a bad year is a question about profits, not about lenders.
$138M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Debt / equity
- 0.00×
Debt / equity
- Annualised volatility
- 94%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $100K
- Cash and short-term investments
- $138M
- Net cash
- $138M
- EBITDA, trailing twelve months
- −$371M
- Operating profit, trailing twelve months
- −$371M
- Debt / equity
- 0.00×
- Annualised volatilitytwo years of daily moves
- 94%
- Worst drawdown on file
- −69%
- Below its 52-week high
- −45%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.